KKR invests in Biosynth Carbosynth

Matt Dixon • Nov 01, 2021

About Biosynth Carbosynth 

Biosynth Carbosynth is a fully hybrid Research Products, Life Sciences Reagents and Custom Synthesis and Manufacturing Services Company with global research, manufacturing and distribution facilities. They are the supplier of choice for many in the pharmaceutical, life science, food, agrochemical, cosmetic and diagnostic sectors and manufacture and source a vast range of chemical and biochemical products. 

About KKR

KKR is a leading global investment firm that offers alternative asset management and capital markets and insurance solutions. 

CCD Partners’ role

CCD Partners’ Gunnar Staaf, Peter Dixon, Roger Green, and Matt Dixon advised KKR on its investment in Biosynth Carbosynth, providing techno-commercial due diligence and strategic advice.

Urs Spitz, CEO and President of Biosynth Carbosynth, commented:

“I would like to thank Armira for our trusting and very successful partnership over the last seven years. I am excited to welcome KKR as our future strategic partner as they have the industry experience, international network, and resources to help us realize our vision of becoming a global platform. KKR’s strategic partnership will enable us to continue to scale the business while retaining the best-in-class product quality, science-led focus, and industry-leading expertise for which our customers have come to know us.”


Kugan Sathiyanandarajah, Managing Director at KKR, commented:

“Reliable, high-quality supply of critical reagents is central to the effective and safe development of diagnostics and therapeutics for the benefit of patients worldwide. We are excited to be working with Urs and Biosynth Carbosynth’s impressive management team, and believe that there is a significant opportunity to build Biosynth Carbosynth into a leading life sciences tools platform." 

Christian Ollig, Partner at KKR, commented:

“This strategic partnership with Biosynth Carbosynth is a fantastic addition to the KKR family, and another example of our strong footprint in the DACH region, our deep expertise in healthcare, and our ability to support family-owned businesses as they move into a new phase of development. Urs is a visionary leader who is highly regarded in Switzerland and beyond, and we are delighted to become part of the company’s exciting future.”



CCD Partners is a consultancy specialised in corporate transformations in small and mid-market chemicals and life sciences businesses.

To organise a call with one of our partners please email contact@ccdpartners.com

Receive M&A news relevant to your business

At critical moments our clients engage us to provide pre-publicity "off-market" intelligence to give them the edge over the competition - we also provide up-to-the-minute public or "on-market" intelligence for free

Contact Us

We're committed to your privacy. CCD Partners uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe at any time. For more information, please see our Privacy Policy.   

RECENT POSTS

By Matt Dixon 05 Dec, 2022
Market leading provider of formulated chemical process aids and foam control, PennWhite has been acquired by Manali Petrochemicals, part of the AM International Holdings group.
By Matt Dixon 02 Dec, 2022
Global source of industrial gas news, views, and debate, gas world has been sold by John and Karen Raquet to the senior management team in an MBO, backed by Mobeus Equity Partners.
By Matt Dixon 13 Sep, 2022
Polyblend UK Ltd is one of the market leaders in PVC based polymers. We are experts in manufacturing a comprehensive range of liquid plastisol and dispersion systems, complemented by our Speciality Distribution business supplying plasticisers, resins and PVC additives.
By Matt Dixon 05 May, 2022
GFBiochemicals is a sustainable chemicals company that produces levulinic acid derivatives at commercial scale directly from biomass. Having perfected its technology, product, and certification, the company is entering a new phase of commercialization.
By CCD Partners 20 Apr, 2022
In the latest episode of the Chemical Transformations podcast , CCD Partners' Managing Partner Matt Dixon speaks with Ted Clark, former President and CEO of Royal Adhesives & Sealants, discussing his new book "Shipping Clerk to CEO: The Power of Curiosity, Will, and Self Directed Learning”. The book tells the story of Clark’s remarkable career journey from entry-level worker to CEO of a $240m chemical company by the age of 42.
By Matt Dixon 04 Feb, 2022
Esteve Química purchases one of the UQUIFA Group's two pharmaceutical fine chemicals plants in Barcelona.
By Matt Dixon 04 Feb, 2022
Specialty materials manufacturer Vertellus has acquired Polyscope Polymers B.V., a global leader in specialty additives for coatings, electronics applications, and engineering polymers.
By CCD Partners 12 Oct, 2021
Steve Allin co-founded Charnwood Molecular with Phil Page in 1998. 22 years later, the business has evolved dramatically from its origins as a spinout of Loughborough University. Backed by a partnership with Synova Capital, the company is now preparing to move into a former AstraZeneca research facility and has already completed its first M&A deal, acquiring Aurelia Bioscience in summer 2021. CCD Partners’ Matt Dixon spoke with Steve about the journey from full-time academia to running a high-growth market leader.
By Matt Dixon 24 Sep, 2021
Aspire was founded in 2009. Aspire has an asset-light business model that focuses on R&D, business development and sales and marketing, while outsourcing manufacturing and distribution to specialist third parties. For more details see www.aspirepharma.co.uk.
By Dr Michelle Lynch 22 Jul, 2021
CCD Partners Senior Advisor Dr Michelle Lynch analyses the net zero roadmaps of five of Europe's leading speciality chemical companies, exploring the details of their strategies and evaluating the real-world impact of their commitments to climate neutrality.
Show More
Share by: